

Relationship between COVID-19 death toll doubling time and national BCG vaccination policy

Yutaka Akiyama* and Takashi Ishida

Department of Computer Science, Tokyo Institute of Technology

*E-mail: akiyama(at)c.titech.ac.jp

Abstract

In this manuscript, we showed a statistically significant difference of the doubling times of the death toll between the group of countries with national universal Bacillus Calmette-Guerin (BCG) vaccination and the group without it for recent years. Based on a statistical test, the distributions of the doubling time of these two groups were significantly different ($p=0.007$). Miller et al. reported the relationship between BCG vaccination and mortality for COVID-19 based on deaths per million inhabitants. However, they did not take into account the differences in COVID-19 detection rates among the countries and the epidemic stages of the countries. Therefore we used a doubling time of the death toll as a more stable indicator instead. We also investigated the dependency of the BCG strains. Among the 42 BCG-vaccinated countries, the median doubling time of the eight countries using "Tokyo 172-1" strain at least partially (Japan, Iraq, Malaysia, South Korea, Philippines, Saudi Arabia, Pakistan, and Bangladesh) was 7.2 days, and that of the other 34 vaccinated countries was 5.5 days. Their distributions were also significantly different ($p=0.026$).

The non-specific effects of Bacillus Calmette-Guerin (BCG) vaccination have been enthusiastically discussed.¹ Miller et al. reported the relationship between BCG vaccination and mortality for COVID-19 based on deaths per million inhabitants.² However they did not take into account the differences in COVID-19 detection rates among the countries and the epidemic stages of the countries. Therefore we used a doubling time (DT) of the death toll as a more stable indicator.

First, we investigated the DT of COVID-19 deaths in 57 countries (source: Our World in Data,³ as of 20 April 2020). We defined the baseline date of each country as the date when summed fatalities of at least ten people was first observed in the country. We covered all countries that have at least 10-day observation period and had a population⁴ of more than 1 million. To exclude the effect of social interventions, the death toll data of the country was truncated by 30 days after the baseline date (for 20 countries among 57).

Next, we surveyed the national BCG vaccination policies of each country (sources: BCG Atlas,⁵ WHO-UNICEF report,⁶ and other 20 papers⁷⁻²⁶). The 57 countries were divided into two groups based on whether the majority of the population between the ages of 0 and 39 was vaccinated ("BCG") or not ("non-BCG"). BCG vaccination records, especially cover rates, are reliable only for the last few decades for several countries. The BCG policy data collected as well as calculated DTs for 57 countries are shown in Table 1.

Figure 1 shows the distributions of DTs. Most of DTs for 42 "BCG" countries are longer than 15 "non-BCG" countries (the medians of the DTs are 5.6 days and 4.2 days, respectively.) The variance of DTs of "BCG" countries was almost same as that of "non-BCG" ($\sigma = 1.7$ and $\sigma = 1.8$, respectively.) Based on a Wilcoxon rank-sum test, the distributions of these two groups were significantly different at the significance level of 0.05 ($p = 0.007$).

We also investigated the dependency of the BCG strains (Figure 2). Among the 42 "BCG" countries, the median DT of the eight countries using "Tokyo 172-1" strain at least partially (Japan, Iraq, Malaysia, South Korea, Philippines, Saudi Arabia, Pakistan, and Bangladesh) was 7.2 days, and that of the other 34 vaccinated countries was 5.5 days. The variance of DTs of "Tokyo 172-1" countries was large ($\sigma = 2.4$) while DTs of "other BCG strains" are relatively concentrated ($\sigma = 1.3$). Their distributions were also significantly different at the significance level of 0.05 ($p = 0.026$).

We showed a statistically significant difference of the doubling times of the death toll between "BCG" and "non-BCG" countries. However, the correlation might be spurious and does not directly imply causality. In addition, we should carefully take the suggested difference between BCG strains, because the number of samples are not enough and some countries are using mixed strains.

The raw data version (an excel file) of Table 1 is available at http://www.bi.cs.titech.ac.jp/COVID-19/Death_vs_BCGpolicy.html.

References:

1. Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. *Clin Microbiol Infect.* 2019; 25(12):1473–1478.
<https://doi.org/10.1016/j.cmi.2019.04.020>
2. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020.03.24.20042937.
<https://doi.org/10.1101/2020.03.24.20042937>
3. Total deaths. Coronavirus Source Data. Our World in Data. Global Change Data Lab. (Release 20 April 2020).
<https://ourworldindata.org/coronavirus-source-data> (last accessed 20 April 2020)
4. World Population Prospects 2019. File POP/1-1: Total population (both sexes combined). The United Nations 2019.
<https://population.un.org/wpp/Download/Standard/Population/> (last accessed 20 April 2020)
5. BCG Atlas (2nd Edition) - A Database of Global BCG Vaccination Policies and Practices
<http://www.bcgatlas.org> (last accessed 20 April 2020)
6. WHO-UNICEF estimates of BCG coverage (1-July-2019). World Health Organization. 2019.

- https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragebcg.html (last accessed 20 April 2020)
7. "BCG Vaccine" (English version). Wikipedia: The Free Encyclopedia. https://en.wikipedia.org/wiki/BCG_vaccine (last accessed 20 Apr. 2020)
 8. The organization and delivery of vaccination services in the European Union. European Observatory on Health Systems and Policies. 2018. https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_services_en.pdf (last accessed 20 Apr. 2020)
 9. Infuso A, Falson D. European survey of BCG vaccination policies and surveillance in children, 2005. *Eurosurveillance* 2006; 11(1-3). <https://www.eurosurveillance.org/upload/site-assets/imgs/2006%201%20v06n01.pdf>
 10. Chen ZR, Wei XH, Zhu ZY. BCG in China. *Chin Med J* 1982; 95(6):437-442. <https://www.ncbi.nlm.nih.gov/pubmed/6813052>
 11. Joung SM, Ryoo S. BCG vaccine in Korea. *Clin Exp Vaccine Res.* 2013; 2(2):83-91. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710928/>
 12. Lahariya C. A brief history of vaccines & vaccination in India. *Indian J Med Res.* 2014; 139(4):491-511. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078488/>
 13. Sweeney E, Dahly D, Seddiq N, Corcoran G, Horgan M, Sadlier C. Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland. *BMC Infect Dis* 2019; 19(397). <https://doi.org/10.1186/s12879-019-4026-z>
 14. Rodrigues EF, Leite A, Cabral M, Duarte G, Marques AP, Cale E, et al. Local Tuberculosis Georeference: a tool to define BCG vaccination in high-incidence area in Portugal. *Eur. J. Public Health* 2019; 29(4). <https://doi.org/10.1093/eurpub/ckz186.532>
 15. Jumaah SA, Hajjar SA, Mousa HA. Bacille Calmette-Guérin Vaccination in Saudi Arabia: Benefits versus Risks. *Ann Saudi Med.* 2012; 32(1): 1–3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087653/>
 16. Pesut D. Contemporary status of BCG vaccine in the world and in Serbia. *Med Pregl.* 2004; 57 Suppl 1:37-40. <https://www.ncbi.nlm.nih.gov/pubmed/15686220>
 17. Gaud J. BCG Vaccination in Morocco. *Maroc Medical* 1954; 33(352):852-59. <https://www.cabdirect.org/cabdirect/abstract/19552702408>
 18. Dirlikov E, Thomas D, Yost D, Tejada-Vera B, Bermudez M, Joglar O, et al. Tuberculosis Surveillance and Control, Puerto Rico, 1898–2015. *Emerg Infect Dis.* 2019;25(3):538-546. <https://dx.doi.org/10.3201/eid2503.181157>

19. De Pinzon TP. BCG Vaccination in the Republic of Panama. *American Review of Tuberculosis* 1953; 67(4):522–525.
<https://www.atsjournals.org/doi/abs/10.1164/art.1953.67.4.522>
20. Govindarajan KK, Chai FY. BCG Adenitis - Need for Increased Awareness. *Malays J Med Sci.* 2011; 18(2): 66–69.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216207/>
21. Tina L, Lamprakou M, Andriopoulos P. Mantoux test and BCG vaccination in elementary schools in Lakonia, Greece 2005-2015. *European Respiratory Journal* 2016; 48:PA2742.
<https://doi.org/10.1183/13993003.congress-2016.PA2742>
22. Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. *Vaccine* 1999; 17(7-8):915-922.
[https://doi.org/10.1016/S0264-410X\(98\)00277-1](https://doi.org/10.1016/S0264-410X(98)00277-1)
23. Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance. *Vaccine* 2018; 36(4):498-506.
<https://doi.org/10.1016/j.vaccine.2017.12.010>
24. The SAGE Working Group on BCG Vaccines and WHO Secretariat. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections. 2017.
https://www.who.int/immunization/sage/meetings/2017/october/1_BCG_report_revised_version_online.pdf (last accessed 20 April 2020)
25. Jou F, Huang WL, Su WJ. Tokyo-172 BCG Vaccination Complications, Taiwan, *Emerg. Infect. Dis.* 2009; 15(9):1525-1526.
<https://doi.org/10.3201/eid1509.081336>
26. Ritz N, Curtis N. Mapping the global use of different BCG vaccine strains. *Tuberculosis* 2009; 89(4):248-251.
<https://doi.org/10.1016/j.tube.2009.03.002>

Authors' contributions:

Y.A. designed the study, and performed literature search, data table compilation, and basic data analysis. T.I. performed the statistical tests, and made figures. Y.A. and T.I. wrote the manuscript.

Funding source:

None

Ethics committee approval:

N/A




Figure 1. The death toll doubling time (DT) of BCG vaccinated ("BCG") and non-vaccinated ("non-BCG") countries




Figure 2. The death toll doubling time (DT) of Tokyo 172-1 ("Tokyo 172-1") and other BCG strains ("Other BCG strains") countries

Country	Population at 2020 estimated (K)	Period start	Total death as of the day: D0	Period end	Total death as of the day: D1	Period length P (day)	Growth rate: R	Doubling time (day)	BCG mass vaccination years	Timing of 1st BCG	Vaccinated age at 2020	Most of 0-39 y/o are vaccinated	BCG strains	Tokyo172-1 strain is used at least partially	BCG policy References
	[4], min 1M		[3]		[3]	min 10 max 30	D1/D0	= P/log2(R)					[5][22][23][24][25][26]		
1 UK	67,886	13-Mar	10	12-Apr	9,875	30	987.5	3.0	1953-2005	12-13 y/o	28-80	No	Glaxo	No	[5][7]
2 France	65,274	8-Mar	10	7-Apr	8,911	30	891.1	3.1	1950-2007	at Birth ?	13-70	Yes	Danish 1331	No	[5][6][7]
3 Italy	60,462	26-Feb	11	27-Mar	8,165	30	742.3	3.1	Limited			No	Danish 1331	No	[5]
4 USA	331,003	5-Mar	11	4-Apr	7,157	30	650.6	3.2	Limited			No		No	[5][7]
5 Spain	46,755	10-Mar	28	9-Apr	14,555	30	519.8	3.3	1965-1981	at Birth	39-55	No	Danish 1331	No	[5][7]
6 Belgium	11,590	19-Mar	14	18-Apr	5,163	30	368.8	3.5	Limited			No	Pasteur 1173	No	[5][7]
7 Germany	83,784	16-Mar	12	15-Apr	3,254	30	271.2	3.7	1961-1998	at Birth	22-69	No	Danish 1331	No	[5][7]
8 Netherlands	17,135	15-Mar	12	14-Apr	2,823	30	235.3	3.8	Limited			No	Bulgaria	No	[5][7]
9 Brazil	212,559	21-Mar	11	20-Apr	2,462	30	223.8	3.8	<1990-2018+	at Birth	0-30+	Yes	Moreau	No	[5][6][7]
10 Russia	145,934	31-Mar	10	20-Apr	361	20	36.1	3.9	<1992-2018+	at Birth	0-28+	Yes	Russia	No	[5][6][7]
11 Mexico	128,933	28-Mar	12	20-Apr	686	23	57.2	3.9	1951-2018+	at Birth	0-69	Yes	Danish 1331	No	[5][6]
12 Iran	83,993	25-Feb	12	26-Mar	2,077	30	173.1	4.0	<1990-2018+	at Birth	0-30+	Yes	Pasteur 1173 P2	No	[5][6][7]
13 Canada	37,742	20-Mar	10	19-Apr	1,467	30	146.7	4.2	Limited			No	Connaught (until 2012), Tokyo 172-1 (from 2012) [5]	No	[5][7]
14 Sweden	10,099	19-Mar	10	18-Apr	1,400	30	140.0	4.2	1940-1975	at Birth	45-80	No	Danish 1331	No	[5][6][7]
15 China	1,439,324	22-Jan	17	21-Feb	2,238	30	131.6	4.3	1949-2018+	at Birth	0-71	Yes	Shanghai D2PB302	No	[5][6][10]
16 Turkey	84,339	22-Mar	21	20-Apr	2,017	29	96.0	4.4	1952-2018+	at Birth	0-68	Yes	Serum Inst. India (Russia)	No	[5][6]
17 Peru	32,972	28-Mar	11	20-Apr	400	23	36.4	4.4	<1990-2018+	at Birth	0-30+	Yes	Danish 1331	No	[5][6]
18 Bangladesh	164,689	7-Apr	12	20-Apr	91	13	7.6	4.4	<1990-2018+	at Birth	0-30+	Yes	Serum Inst. India (Russia) [5], Tokyo 172-1 [11]	Yes	[5][6][11]
19 India	1,380,004	26-Mar	13	20-Apr	543	25	41.8	4.6	1951-2018+	at Birth	0-69	Yes	Danish 1331	No	[5][6][7][12]
20 Switzerland	8,655	15-Mar	11	14-Apr	858	30	78.0	4.8	1960s-1987	at Birth	33-50+	No	Merieux (Danish)	No	[5]
21 Ireland	4,938	27-Mar	19	20-Apr	610	24	32.1	4.8	1950s-2003?	at Birth	17-60+	Yes	Danish 1331	No	[5][6][7][13]
22 Romania	19,238	25-Mar	11	20-Apr	434	26	39.5	4.9	1928-2018+	at Birth	0-92	Yes	Romanian BCG substrain Catacuzino Institute	No	[5][6][7]
23 Portugal	10,197	22-Mar	12	20-Apr	714	29	59.5	4.9	1965-2015	at Birth	5-55	Yes	Danish 1331	No	[5][6][7][8][14]
24 Poland	37,847	25-Mar	10	20-Apr	360	26	36.0	5.0	1955-2018+	at Birth	0-65	Yes	Danish 1331	No	[5][6][7]
25 Colombia	50,883	30-Mar	10	20-Apr	179	21	17.9	5.0	<1980-2018+	at Birth	0-40+	Yes	Pasteur 1173	No	[5][6]
26 Ukraine	43,734	31-Mar	11	20-Apr	151	20	13.7	5.3	<1992-2018+	at Birth	0-28+	Yes	Bulgaria NCIPD	No	[5][6]
27 Czechia	10,709	29-Mar	11	20-Apr	188	22	17.1	5.4	1965-2010	at Birth	10-67	Yes	Moreau	No	[5][6][7]
28 Chile	19,116	1-Apr	12	20-Apr	133	19	11.1	5.5	<1980-2018+	at Birth	0-40+	Yes	Danish 1331	No	[5][6]
29 Pakistan	220,892	29-Mar	11	20-Apr	176	22	16.0	5.5	1978-2018+	at Birth	0-42	Yes	Danish 1331 (until 2007), Tokyo 172-1 (from 2008) [5][11]	Yes	[5][6][7][11]
30 Ecuador	17,643	23-Mar	14	20-Apr	474	28	33.9	5.5	<1995-2018+	at Birth	0-25+	Yes	Russia/Bulgaria	No	[5][6]
31 Dominican Republic	10,848	26-Mar	10	20-Apr	226	25	22.6	5.6	<1990-2018+	at Birth	0-30+	Yes	Russia/Bulgaria	No	[5][6]
32 Israel	8,656	28-Mar	10	20-Apr	172	23	17.2	5.6	1955-1982	at Birth	38-65	No		No	[5][6][7]
33 Algeria	43,851	21-Mar	10	20-Apr	375	30	37.5	5.7	<1985-2018+	at Birth	0-35+	Yes		Unknown	[5][6]
34 Saudi Arabia	34,814	1-Apr	10	20-Apr	97	19	9.7	5.8	<1985-2018+	at Birth	0-35+	Yes	Pasteur [5], Danish 1331 [15], Tokyo 172-1 [11]	Yes	[5][6][11][15]
35 Austria	9,006	23-Mar	16	20-Apr	452	28	28.3	5.8	1952-1990	at Birth	30-68	No		No	[5][6][7]
36 Hungary	9,660	25-Mar	10	20-Apr	199	26	19.9	6.0	1953-2018+	at Birth	0-67	Yes	Danish 1331	No	[5][6][7]
37 Moldova	4,034	5-Apr	12	20-Apr	67	15	5.6	6.0	<1992-2018+	at Birth	0-28+	Yes		Unknown	[5][6]
38 Denmark	5,792	22-Mar	13	20-Apr	355	29	27.3	6.1	1946-1986	at Birth	34-74	No	Danish 1331	No	[5][7]
39 Serbia	8,737	29-Mar	10	20-Apr	122	22	12.2	6.1	<1992-2018+	at Birth	0-28+	Yes	Pasteur 1173 P2	No	[6][7][16]
40 South Africa	59,309	6-Apr	11	20-Apr	54	14	4.9	6.1	<1995-2011+	at Birth	0-25+	Yes	Danish 1331	No	[5][6][7]
41 Egypt	102,334	23-Mar	10	20-Apr	239	28	23.9	6.1	<1990-2018+	at Birth	0-30+	Yes		Unknown	[5][6]
42 Indonesia	273,524	20-Mar	19	19-Apr	535	30	28.2	6.2	<1990-2018+	at Birth	0-30+	Yes	Pasteur 1173	No	[5][6]
43 Philippines	109,581	16-Mar	12	15-Apr	335	30	27.9	6.2	1979-2018+	at Birth	0-41	Yes	Tokyo 172-1, and others? (hearing from Japan BCG Lab.)	Yes	[5][6][7]
44 Morocco	36,911	27-Mar	10	20-Apr	141	24	14.1	6.3	1949-2018+	at Birth	0-71	Yes		Unknown	[5][6][7][17]
45 Norway	5,421	25-Mar	10	20-Apr	154	26	15.4	6.6	1947-2009	at Birth	11-73	Yes	Danish 1331	No	[5][7]
46 Finland	5,541	30-Mar	11	20-Apr	94	21	8.5	6.8	1941-2006	at Birth	14-79	Yes	Glaxo, Danish 1331	No	[5][6][7]
47 Argentina	45,196	27-Mar	12	20-Apr	134	24	11.2	6.9	<1985-2018+	at Birth	0-35+	Yes	Anlis Malbran (Pasteur)	No	[5][6]
48 Puerto Rico	2,861	2-Apr	11	20-Apr	62	18	5.6	7.2	Limited?			No		No	[18]
49 Panama	4,315	28-Mar	14	20-Apr	126	23	9.0	7.3	<1980-2018+	at Birth	0-40+	Yes	Russia/Bulgaria	No	[5][6][19]
50 Slovenia	2,079	30-Mar	11	20-Apr	74	21	6.7	7.6	1947-2005	at Birth	15-73	Yes	Danish 1331	No	[5][6]
51 Macedonia	2,083	2-Apr	10	20-Apr	51	18	5.1	7.7	<1993-2018+	at Birth	0-27+	Yes	Tronto Canada (Connaught)	No	[5][6]
52 S. Korea	51,269	26-Feb	11	27-Mar	139	30	12.6	8.2	1970s-2018+	at Birth	0-40+	Yes	Tokyo 172-1 [11][25], Danish [5]	Yes	[5][6][7][11][25]
53 Malaysia	32,366	23-Mar	10	20-Apr	89	28	8.9	8.9	<1980-2018+	at Birth	0-40+	Yes	Tokyo 172-1 [20]	Yes	[5][6][7][20]
54 Australia	25,500	26-Mar	11	20-Apr	70	25	6.4	9.4	1950s-1985?	school age	40-70	No	Connaught (until 2010s)	No	[5][7]
55 Greece	10,423	22-Mar	13	20-Apr	110	29	8.5	9.4	<1980-2014+	6 y/o	12-46+	Yes	Danish 1331	No	[5][6][7][21]
56 Iraq	40,223	18-Mar	11	17-Apr	80	30	7.3	10.5	<1980-2018+	at Birth	0-40+	Yes	Tokyo 172-1 [26]	Yes	[5][6]
57 Japan	126,476	11-Mar	12	10-Apr	85	30	7.1	10.6	<1951-2020	at Birth	0-69+	Yes	Tokyo 172-1 [11][25]	Yes	[5][6][7][11][25]

p = 0.007
Wilcoxon
rank sum
test

p = 0.026
Wilcoxon
rank sum
test